Released on November 16, 2011

Recently, Haemocoagulase Agkistrodon for Injection (KLN), a new drug jointly developed by the Center, Guangdong Rexan Pharmaceutical Co., Ltd and Guangdong Sincody Pharmaceutical Development Co., Ltd, has obtained the approval document for the Phase II clinical test issued by State Food and Drug Administration (SFDA).

After the project approval for development in 2000, the pre-clinical studies and the Phase I clinical test study on the KLN have indicated that the drug has a significant hemostatic effect, with good safety and reasonable pharmacokinetic characteristics. Obtaining the approval document for the Phase II clinical test this time is a sign that the R& D of the drug has made an important staged progress. 

The hemostatic drug market in China is very huge, with the hemostatic drug sales volume of 2 billion yuan in 2004, and the market space is increasing year by year. In the domestic 2-billion-yuan hemostatic drug market field, Haemocoagulase drugs are developing rapidly in our hospital hemostatic drug market, with the annual average sales growth rate of the recent 5 years up to 38%, accounting for about 60% of the hemostatic drug market share.